| Literature DB >> 31549492 |
Arun K Ghosh1, Zilei Xia1, Satish Kovela1, William L Robinson1, Megan E Johnson1, Daniel W Kneller2, Yuan-Fang Wang2, Manabu Aoki3,4, Yuki Takamatsu4, Irene T Weber2, Hiroaki Mitsuya5,3,4.
Abstract
We report the synthesis and biological evaluation of phenylcarboxylic acid and phenylboronic acid containing HIV-1 protease inhibitors and their functional effect on enzyme inhibition and antiviral activity in MT-2 cell lines. Inhibitors bearing bis-THF ligand as P2 ligand and phenylcarboxylic acids and carboxamide as the P2' ligands, showed very potent HIV-1 protease inhibitory activity. However, carboxylic acid containing inhibitors showed very poor antiviral activity relative to carboxamide-derived inhibitors which showed good antiviral IC50 value. Boronic acid derived inhibitor with bis-THF as the P2 ligand showed very potent enzyme inhibitory activity, but it showed lower antiviral activity than darunavir in the same assay. Boronic acid containing inhibitor with a P2-Crn-THF ligand also showed potent enzyme Ki but significantly decreased antiviral activity. We have evaluated antiviral activity against a panel of highly drug-resistant HIV-1 variants. One of the inhibitors maintained good antiviral activity against HIVDRV R P20 and HIVDRV R P30 viruses. We have determined high resolution X-ray structures of two synthetic inhibitors bound to HIV-1 protease and obtained molecular insight into the ligand-binding site interactions.Entities:
Keywords: HIV-1 protease inhibitors; brain penetration; drug resistance; genetic barriers; structure-based design
Year: 2019 PMID: 31549492 PMCID: PMC6842059 DOI: 10.1002/cmdc.201900508
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466